Novel structured diacylglycerol (DAG) rich oleo formulations activate the Nrf2 pathway and impedes NF-κB translocation to mitigate pre-clinical conditions of hypertension

The objective of the present work was to assess the ameliorative potential of two novel edible diacylglycerol oil-formulations comprising caprylic acid, C8:0 or capric acid, C10:0 in treating CdCl2 induced in vivo hypertension at molecular level.Male Wistar rats were randomly divided into 4 groups (1) control; (2) DAG oil-treated group (2 gm/day DAG oil); (3) hypertensive group (1.0 mg/kg of CdCl2 for 2 weeks, i. p); and (4) hypertensive/DAG oil-treated group (2 gm/day DAG oil) (14 days). Hematological, biochemical and molecular parametric tools were performed to evaluate the protective efficacy of DAG oils against CdCl2-induced hypertension. Systolic blood pressure (SBP) measured non-invasively using BIOPAC-MP36 system (BIOPAC System Inc., USA). It was found that the pretreatment of DAG oil provided a significant improvement in renal antioxidant status, reduced the lipid peroxidation and the levels of inflammatory markers that were aggravated due to induced CdCl2-toxicity. Further, results of protein expression showed that DAG oil pretreatment normalized the renal expression of Nrf2/Keap1 and its downstream regulatory proteins in CdCl2-treated rat kidney. DAG oils also effectively attenuated CdCl2-induced renal apoptosis by the up-regulation of anti-apoptotic proteins such as Bcl-2 and down-regulation of Bax, caspase-3, caspase-9 and Cytochrome c. Histological and immunohistochemical observations provided further evidence that the DAG oils effectively protected the kid...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research